PSEN1 & CDK2 Antibodies: Core Research Tools for Neurodegeneration and Tumor Biology

Concept

Presenilin-1 (PSEN1) and Cyclin-Dependent Kinase 2 (CDK2) represent two pivotal molecular targets in distinct yet equally impactful areas of life science research—Alzheimer’s disease (AD) and cancer biology, respectively. PSEN1, a 467-amino acid transmembrane protein and the catalytic core of the γ-secretase complex, is encoded by the PSEN1 gene on human chromosome 14q24.2; its pathogenic mutations are the most common genetic cause of familial early-onset AD, driving neurotoxic Aβ42 peptide production and disrupting critical neuronal pathways (Notch, Wnt/β-catenin, calcium homeostasis). CDK2, a serine/threonine kinase and master regulator of the G1-to-S cell cycle transition, is a key driver of uncontrolled tumor proliferation; its abnormal activation—via cyclin E amplification, MYC overexpression, or loss of CDK inhibitors—underpins tumorigenesis in ovarian, lung, breast, and neuroblastoma cancers, and serves as the primary compensatory pathway for CDK4/6 inhibitor resistance. PSEN1 and CDK2-specific antibodies are indispensable research tools for unraveling the molecular mechanisms of AD and cancer, enabling precise detection, localization, and functional characterization of these targets in cells, tissues, and preclinical models. As high-specificity reagents engineered to overcome technical challenges (CDK family homology, PSEN1/PSEN2 paralog similarity), these antibodies underpin basic mechanistic research, biomarker development, and the discovery of novel therapeutics for two of the world’s most devastating diseases.

Research Frontiers

PSEN1 and CDK2 antibody research are dynamic frontiers in neurodegeneration and oncology, with cutting-edge applications focused on translating basic molecular insights into clinical solutions—while also advancing cross-disciplinary understanding of shared cellular pathways (e.g., autophagy, cell cycle dysregulation). Key research frontiers for these antibodies include:

PSEN1 Antibody Research Frontiers

1. Spatial and single-cell analysis of PSEN1 in the AD brain: Combining PSEN1 antibodies with spatial transcriptomics and multiplex immunofluorescence to map PSEN1 expression/ localization in distinct neuronal and glial cell subsets, and correlate with Aβ plaque and neurofibrillary tangle formation in the AD brain.
2. Mutant PSEN1 functional characterization: Engineering PSEN1 antibodies targeting disease-causing mutation sites (e.g., missense, frameshift) to study mutant protein stability, γ-secretase complex assembly, and subcellular localization in iPSC-derived neurons and AD brain organoids.
3. PSEN1 fragment detection in biofluids: Developing PSEN1 antibody-based immunoassays for quantitative detection of PSEN1 NTF/CTF proteolytic fragments in cerebrospinal fluid (CSF) and peripheral blood, enabling non-invasive AD diagnosis and disease progression monitoring.
4. γ-secretase modulator validation: Using PSEN1 antibodies to evaluate the efficacy of novel γ-secretase modulators/inhibitors in preclinical AD models, measuring changes in PSEN1 expression, complex assembly, and Aβ42/Aβ40 ratios.

CDK2 Antibody Research Frontiers

1. Phospho-specific CDK2 antibody development: Engineering antibodies targeting CDK2’s activating phosphorylation sites (Thr160) to study dynamic activation states in tumor cells, and correlate with CDK4/6 inhibitor resistance in clinical samples.
2. CDK2 heterogeneity in the tumor microenvironment (TME): Using CDK2 antibodies with single-cell RNA sequencing to map CDK2 expression across cancer and stromal cells in the TME, defining cell-type-specific reliance on CDK2 for proliferation.
3. Liquid biopsy-based CDK2 biomarker detection: Developing CDK2 antibody immunoassays for circulating tumor cells (CTCs) and extracellular vesicles (EVs), enabling real-time monitoring of treatment response in cancer patients.
4. CDK2 interaction network mapping: Using Co-IP and proximity ligation assay (PLA) with CDK2 antibodies to identify novel binding partners, uncovering non-canonical CDK2 functions in DNA damage repair and metabolic reprogramming.

Cross-Disciplinary Research Frontiers

PSEN1 and CDK2 antibodies also enable exploration of shared cellular pathways in neurodegeneration and cancer, including autophagy dysregulation (PSEN1 modulates autophagy in neurons; CDK2 regulates autophagy in tumor cells) and cell cycle re-entry in post-mitotic neurons (a hallmark of AD pathogenesis), blurring the line between neurobiology and oncology research.

Research Significance

PSEN1 and CDK2 antibodies are foundational research tools with profound and far-reaching significance for basic science, translational research, and clinical drug development—addressing unmet medical needs in AD and cancer, two leading causes of global mortality:

PSEN1 Antibodies: Transforming Alzheimer’s Disease Research

1. Unraveling AD’s genetic and molecular mechanisms: PSEN1 antibodies enable the precise characterization of pathogenic PSEN1 mutations, defining how these alterations disrupt γ-secretase activity, Aβ metabolism, and neuronal signaling pathways—providing the mechanistic basis for novel AD therapeutics.
2. Accelerating AD drug discovery: As gold-standard detection tools, PSEN1 antibodies are critical for validating γ-secretase modulators, anti-Aβ therapies, and PSEN1-targeted drugs in preclinical AD models (transgenic mice, iPSC neurons), streamlining the preclinical drug development pipeline.
3. Enabling AD biomarker development: PSEN1 antibodies facilitate the development of CSF/blood-based biomarkers for AD diagnosis and progression monitoring, addressing the critical need for non-invasive, early detection tools for this neurodegenerative disease.
4. Validating preclinical AD models: PSEN1 antibodies verify genetic modification and mutant PSEN1 expression in transgenic AD models, ensuring these models accurately recapitulate human disease pathology and are reliable for therapeutic testing.

CDK2 Antibodies: Advancing Cancer Biology and Precision Oncology

1. Defining CDK2’s role in tumorigenesis and drug resistance: CDK2 antibodies characterize the abnormal activation of CDK2 in a broad spectrum of cancers, and validate its role as the primary compensatory pathway for CDK4/6 inhibitor resistance—paving the way for combination CDK2/4/6 inhibition strategies.
2. Empowering precision cancer therapy: CDK2 antibodies enable the correlation of CDK2/cyclin E expression with clinical outcomes in cancer patients, identifying predictive biomarkers that select patients most likely to benefit from CDK2-targeted therapy and avoid ineffective treatment.
3. Accelerating CDK2 inhibitor development: CDK2 antibodies are essential for evaluating the efficacy of novel CDK2 inhibitors and multi-target CDK2/4/6 agents in vitro (cell lines) and in vivo (PDX models), from kinase activity assays to tumor proliferation studies.
4. Bridging basic cell cycle biology and clinical oncology: Validated IHC-grade CDK2 antibodies enable the analysis of CDK2 expression in formalin-fixed paraffin-embedded (FFPE) clinical samples, translating basic cell cycle research into clinical practice and biomarker development.

Combined Significance

Together, PSEN1 and CDK2 antibodies represent ANT BIO’s commitment to providing high-performance research tools for the most pressing areas of biomedical research. By enabling precise, reliable detection of these pivotal targets, these antibodies drive breakthroughs in our understanding of AD and cancer, and accelerate the development of life-saving therapeutics for millions of patients worldwide.

Mechanisms & Research Methods

1. Core Molecular Mechanisms of PSEN1 (AD) and CDK2 (Cancer)

Presenilin-1 (PSEN1): Catalytic Core of γ-Secretase and AD Pathogenesis

PSEN1 is the catalytic subunit of the γ-secretase complex (alongside Nicastrin, APH-1, PEN-2), a multi-subunit protease responsible for intramembranous cleavage of type I transmembrane proteins—with two critical roles in neuronal biology and AD:

• Amyloid Precursor Protein (APP) cleavage: γ-secretase cleaves APP to generate amyloid-β (Aβ) peptides; pathogenic PSEN1 mutations alter γ-secretase substrate specificity, increasing the production of the neurotoxic 42-amino acid Aβ42 peptide (the primary component of AD amyloid plaques).
• Notch/Wnt signaling regulation: γ-secretase cleaves the Notch receptor to release its intracellular domain (NICD), a critical step in neural development and synaptic plasticity; PSEN1 dysfunction also disrupts Wnt/β-catenin signaling and neuronal calcium homeostasis, leading to synaptic loss and neuronal death.
• Proteolytic processing: PSEN1 is constitutively cleaved into N-terminal (NTF) and C-terminal (CTF) fragments, which form the active γ-secretase complex—an event disrupted by AD-associated PSEN1 mutations.

Pathogenic PSEN1 mutations (over 300 identified) are the most common cause of familial early-onset AD (FEOAD), accounting for ~50% of FEOAD cases, and drive AD pathogenesis via multiple, interconnected mechanisms (Aβ overproduction, signaling dysregulation, autophagy impairment).

Cyclin-Dependent Kinase 2 (CDK2): Cell Cycle Regulator and Tumor Oncogene

CDK2 is a master regulator of the G1-to-S phase cell cycle transition—the irreversible point of cell commitment to proliferation—with a well-characterized role in normal cell cycle progression and a dysregulated role in tumorigenesis:

• Normal cell cycle function: CDK2 binds cyclin E (G1 phase) to hyperphosphorylate the retinoblastoma protein (Rb), releasing E2F transcription factors and driving S-phase gene expression; in S phase, it binds cyclin A to regulate DNA replication and prevent re-replication.
• Tumorigenic activation: Tumor cells disrupt CDK2 regulation via cyclin E amplification, MYC/MYCN overexpression, loss of CDK inhibitors (p21/p27), or KRAS mutation—leading to constitutive CDK2 activation and uncontrolled proliferation.
• Drug resistance driver: CDK2 is the primary compensatory pathway for CDK4/6 inhibitor resistance in ER+/HER2- breast cancer; when CDK4/6 activity is inhibited, tumor cells upregulate CDK2-cyclin E to sustain Rb phosphorylation and cell cycle progression.

CDK2 activation is tumor-selective (most normal tissues have low dependence on CDK2), making it a highly attractive therapeutic target for cancer therapy—particularly for overcoming CDK4/6 inhibitor resistance.

2. Technical Challenges in PSEN1 and CDK2 Antibody Development

PSEN1 and CDK2 antibody development face unique technical challenges, stemming from structural homology, conformational dynamics, and post-translational modification—overcome by ANT BIO’s advanced recombinant antibody engineering and epitope design:

3. Key Applications of PSEN1 and CDK2 Antibodies in Research

Both PSEN1 and CDK2 antibodies are versatile, multi-application research tools, validated for the most critical techniques in neurobiology, oncology, and translational research—enabling mechanistic studies, biomarker development, and drug discovery.

PSEN1 Antibodies: Key Applications in Alzheimer’s Disease Research

1. Protein Expression & Localization Analysis
• Immunohistochemistry (IHC): Detect PSEN1 expression in human AD brain tissue and preclinical model brains; map localization to neurons, astrocytes, and microglia, and correlate with Aβ plaque formation.
• Immunofluorescence (IF/ICC): Visualize subcellular localization of PSEN1 (endoplasmic reticulum, Golgi, cell membrane) in neurons; track changes in localization caused by pathogenic mutations.
• Western Blot (WB): Detect full-length PSEN1 and NTF/CTF fragments in brain tissue lysates and iPSC-derived neurons; quantify changes in expression/processing in AD models.
2. Functional & Complex Interaction Analysis
• Co-Immunoprecipitation (Co-IP): Capture the γ-secretase complex (PSEN1 + Nicastrin/APH-1/PEN-2) and PSEN1-interacting proteins; study complex assembly and disruption by pathogenic mutations.
• Immunoprecipitation (IP): Isolate PSEN1 for in vitro γ-secretase activity assays; evaluate the effect of γ-secretase modulators on complex activity.
3. Translational & Drug Discovery Research
• Biomarker Development: Develop antibody-based immunoassays for PSEN1 fragments in CSF/blood; enable non-invasive AD diagnosis and progression monitoring.
• Preclinical Model Validation: Verify mutant PSEN1 expression and processing in transgenic AD mice, iPSC neurons, and brain organoids.
• Drug Efficacy Evaluation: Use PSEN1 antibodies to evaluate γ-secretase modulators/inhibitors; measure changes in PSEN1 expression, complex assembly, and Aβ42/Aβ40 ratios.

CDK2 Antibodies: Key Applications in Cancer Research

1. Protein Expression & Localization Analysis
• IHC: Quantify CDK2 expression in FFPE tumor samples (ovarian, breast, lung); correlate with tumor grade, stage, and patient outcomes for biomarker development.
• IF/ICC: Visualize nuclear CDK2 localization in tumor cells; track changes in localization during the cell cycle and in response to CDK inhibitor therapy.
• WB: Measure CDK2 protein levels in tumor cell lines and PDX models; detect compensatory CDK2 activation in CDK4/6-resistant cells.
2. Functional & Interaction Analysis
• Co-IP/IP: Capture CDK2-cyclin E/A complexes; study interaction dynamics and disruption by CDK inhibitors; isolate active CDK2 for in vitro kinase activity assays.
• PLA: Detect in situ CDK2-cyclin E interactions in the TME; map cell-type-specific complex formation in cancer and stromal cells.
3. Translational & Drug Discovery Research
• Biomarker Validation: Correlate CDK2/cyclin E expression with CDK4/6 inhibitor response in clinical patient cohorts; enable patient stratification for precision oncology.
• Resistance Mechanism Analysis: Characterize CDK2 activation in CDK4/6-resistant tumor samples; validate the CDK2 pathway as a therapeutic target for combination therapy.
• Inhibitor Screening: Use CDK2 antibodies to evaluate novel CDK2/4/6 inhibitors; measure changes in CDK2 expression, phosphorylation, and downstream Rb/E2F signaling.

Product Empowerment: ANT BIO’s High-Performance PSEN1 & CDK2 Antibodies (Starter Sub-brand)

As a global leader in life science research reagents, ANT BIO PTE. LTD. offers a gold-standard portfolio of PSEN1 and CDK2 recombinant rabbit monoclonal antibodies via our Starter sub-brand—the flagship antibody specialist for neurodegeneration and oncology research. Engineered using ANT BIO’s advanced S-RMab® recombinant antibody platform, these antibodies overcome the technical challenges of target homology, conformational dynamics, and complex sample analysis, delivering unmatched specificity, broad application validation, and exceptional batch consistency. Our PSEN1 and CDK2 antibodies are rigorously tested and validated for WB, IHC, IF, and IP—the four most critical techniques for AD and cancer research—and are supported by comprehensive technical documentation, optimized experimental protocols, and expert scientific support. Complemented by our Absin (general life science reagents/kits) and UA (recombinant proteins) sub-brands, ANT BIO provides a one-stop research toolkit for PSEN1 and CDK2 studies, enabling seamless research from basic molecular mechanistic studies to preclinical drug discovery—with a single, trusted supplier.

Core Advantages of ANT BIO’s PSEN1 & CDK2 Antibodies

Key Application Synergies & Complementary Tools

• Absin Sub-brand: Provides IHC/WB/IP buffers, brain/tumor tissue lysate kits, CSF/blood sample preparation reagents, and cell culture media—supporting all experimental workflows for PSEN1 and CDK2 research.
• UA Sub-brand: Offers human recombinant CDK2 protein (UA080212) for in vitro kinase assays and CDK2 inhibitor screening—complementing our CDK2 antibodies for drug discovery research (recombinant PSEN1 protein available on inquiry).

Brand Mission

At ANT BIO PTE. LTD., our core mission is to empower breakthrough research in neurodegeneration and oncology by providing high-quality, innovative, and validated research tools for pivotal molecular targets such as PSEN1 and CDK2. As a leading global provider of life science reagents, we have built three specialized sub-brands that cover the full spectrum of research needs—from basic molecular biology to preclinical drug discovery and clinical translation—creating a seamless one-stop procurement experience for academic researchers, biotech companies, and pharmaceutical institutions worldwide:

• Absin: Specializes in general life science reagents and kits, including assay buffers, tissue lysate kits, sample preparation reagents, and cell culture media—supporting the experimental workflows for all PSEN1 (AD) and CDK2 (cancer) research applications.
• Starter: Our flagship antibody specialist sub-brand, engineering high-performance recombinant monoclonal antibodies for neurodegeneration (PSEN1) and oncology (CDK2, PD-1, FOLR1) targets—with core expertise in multi-application validated antibodies for complex sample analysis (brain tissue, tumor FFPE).
• UA: Dedicated to recombinant proteins and custom protein services, including human recombinant CDK2 protein, kinase proteins, and custom protein expression/purification—specializing in biologically active proteins for in vitro assays and drug screening (custom PSEN1/γ-secretase complex proteins available on inquiry).

We are committed to overcoming the technical challenges of targeting complex proteins (PSEN1, CDK2) and providing research tools that drive scientific discovery and therapeutic development for AD and cancer—two of the world’s most devastating diseases. With rigorous quality control, expert technical support, and a customer-centric approach, we strive to be your trusted partner in every step of your research journey—from basic lab experiments to clinical translation.

Related Product List: ANT BIO’s PSEN1 & CDK2 Research Tools (Starter & UA Sub-brands)

All products are rigorously validated, quality-controlled, and optimized for key research applications in Alzheimer’s disease and cancer biology—with batch-to-batch consistency and comprehensive technical support.

For detailed product specifications, bulk pricing, custom antibody conjugation (fluorochrome/biotin), recombinant protein engineering (including custom PSEN1/γ-secretase complex proteins), or sample testing requests, please visit the ANT BIO official website or contact our sales team for a personalized quote and technical consultation. We provide comprehensive validation data packages for all antibodies, including species cross-reactivity, application optimization, and representative result images for brain/tumor tissue samples.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please inform us immediately, and we promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.